Last Updated: May 10, 2026

CLINICAL TRIALS PROFILE FOR SORIATANE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for SORIATANE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00156247 ↗	Acitretin and Etanercept in Psoriasis	Completed	Connetics Corp.	Phase 2	2005-09-01	To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT00156247 ↗	Acitretin and Etanercept in Psoriasis	Completed	University of Medicine and Dentistry of New Jersey	Phase 2	2005-09-01	To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT01545284 ↗	Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Completed	Tribute Pharmaceuticals	Phase 2/Phase 3	2012-03-01	This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .
NCT01545284 ↗	Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Completed	Innovaderm Research Inc.	Phase 2/Phase 3	2012-03-01	This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .
NCT02050321 ↗	A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma	Terminated	University of Arizona	Phase 2	2013-12-01	We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for SORIATANE

Condition Name

Chart
Table

Condition Name for SORIATANE
Intervention	Trials
Chronic Hand Dermatitis	1
Dermatomyositis, Adult Type	1
Malignant Melanoma	1
Netherton Syndrome	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for SORIATANE
Intervention	Trials
Dermatomyositis	1
Syndrome	1
Netherton Syndrome	1
Melanoma	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SORIATANE

Trials by Country

Map
Table

Trials by Country for SORIATANE
Location	Trials
United States	2
Canada	2
France	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for SORIATANE
Location	Trials
Louisiana	1
Arizona	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SORIATANE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for SORIATANE
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for SORIATANE
Clinical Trial Phase	Trials
Completed	4
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SORIATANE

Sponsor Name

Chart
Table

Sponsor Name for SORIATANE
Sponsor	Trials
Innovaderm Research Inc.	1
University of Arizona	1
Assistance Publique - Hôpitaux de Paris	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for SORIATANE
Sponsor	Trials
Other	6
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.